Trial Profile
A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy (Tamoxifen/Medroxyprogesterone Acetate) in Women With Advanced, Recurrent, or Persistent Endometria Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Letrozole (Primary) ; Medroxyprogesterone; Tamoxifen
- Indications Endometrial cancer
- Focus Therapeutic Use
- 16 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 13 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 18 Feb 2015 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.